Vanguard Capital Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Vanguard Capital Management's IBRX Position: Q3 2026 in Review
Vanguard Capital Management increased its ImmunityBio (IBRX) stake by 20% in Q3 2026, buying an estimated $24.9M and bringing the position to 18,804,937 shares worth $178M. The position accounts for ﹤0.01% of the portfolio, ranked #1177.
Vanguard Capital Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Vanguard Capital Management held 18,804,937 shares of ImmunityBio worth $178M as of Q3 2026.
- Vanguard Capital Management bought 3,113,358 ImmunityBio shares in Q3 2026, an estimated $24.9M.
- ImmunityBio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1177 holding.
- Vanguard Capital Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
- 405 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.